Most of the story told about Wegovy and fatty liver disease runs through weight. The medicine helps people lose a substantial amount of it, and improvements in liver fat, inflammation and metabolic health often follow.
That explanation leaves an awkward group out of the picture.
Some people develop metabolic dysfunction-associated steatohepatitis, or MASH, without having obesity. Their livers can become inflamed and scarred even when their body weight does not fit the usual profile associated with metabolic liver disease.
At the American Association for the Study of Liver Diseases’ Liver Meeting in Denver, held November 5–9, 2026, researchers presented a new analysis of Wegovy in precisely that kind of population.
The analysis examined 106 participants in the Phase 3 ESSENCE trial whose body mass index was below 27. After 72 weeks, several measures of liver injury, disease activity and fibrosis favored semaglutide 2.4 mg over placebo.
That is an encouraging finding. It is also an exploratory analysis of a small subgroup, not a clinical trial specifically designed to establish how well semaglutide works in patients without obesity.
The distinction matters because the results raise an important question about Wegovy fatty liver treatment: does a patient’s body weight determine how much the liver can benefit?
These new data suggest the answer may be more complicated than weight alone. They do not establish why the improvements occurred.
What the ESSENCE Trial Established About Wegovy and Fatty Liver Disease
ESSENCE is an ongoing Phase 3 clinical trial investigating once-weekly semaglutide 2.4 mg in adults with MASH and moderate to advanced liver fibrosis, classified as stages F2 and F3.
MASH is the inflammatory form of metabolic dysfunction-associated steatotic liver disease. It involves liver fat accumulation, inflammation and cellular injury, and can progress to fibrosis, cirrhosis and serious liver complications.
The trial has two parts. The first evaluates changes in liver tissue after 72 weeks of treatment. The second follows participants for 240 weeks to assess whether improvements in liver disease translate into fewer serious clinical events.
The first 800 randomized participants formed the population for the planned interim analysis published in the New England Journal of Medicine in 2025.
Of those participants, 534 were assigned to semaglutide and 266 to placebo.
The results were substantial.
After 72 weeks, 62.9% of participants receiving semaglutide achieved resolution of steatohepatitis without worsening of liver fibrosis, compared with 34.3% receiving placebo.
The second primary outcome examined fibrosis improvement without worsening of steatohepatitis. That occurred in 36.8% of semaglutide-treated participants versus 22.4% in the placebo group.
Both primary comparisons favored semaglutide and were statistically significant.
These findings supported the US Food and Drug Administration’s accelerated approval of Wegovy on August 15, 2025, for adults with noncirrhotic MASH and moderate to advanced fibrosis.
The MASH indication is distinct from Wegovy’s weight-management indication. It is defined by liver disease and fibrosis severity rather than a minimum BMI requirement.
But accelerated approval comes with an important condition. The existing evidence demonstrates improvement in liver histology, meaning what liver tissue looks like under microscopic examination. It does not yet establish that treatment prevents liver failure, transplantation or death.
ESSENCE’s ongoing second phase is intended to answer that question.
Wegovy has demonstrated improvement in liver tissue. Whether that translates into fewer serious liver complications is still being tested.
The 106 Participants Who Were Not Obese
The new analysis, presented by Jörn Schattenberg of Saarland University Medical Center in Germany, focused on the 106 participants whose baseline BMI was below 27 kg/m².
That represents approximately 13% of the 800 participants included in ESSENCE’s first interim analysis.
The distinction between lower BMI and genuinely lean body composition matters.
A BMI below 27 does not necessarily mean someone is lean. It includes people conventionally classified as having overweight, and BMI thresholds have different clinical implications across populations.
The more accurate description is therefore patients with MASH and BMI below 27, rather than assuming that every participant had low body fat.
The subgroup was also demographically distinctive.
According to the presentation summarized by HCPLive, 67.9% were women, 68.9% were Asian and 52.8% had type 2 diabetes.
Those characteristics matter because metabolic liver disease can develop at different body weights across populations. They also limit how confidently these findings can be generalized to every patient with a BMI below 27.
The subgroup was drawn from a randomized trial, which is a strength. But the subgroup analysis itself was conducted after the main trial design was established.
That makes it post hoc and exploratory.
Randomization in the overall ESSENCE population does not guarantee that every clinical characteristic was equally balanced within a subgroup of only 106 people.
There is another important detail.
Novo Nordisk states that histological findings for both primary ESSENCE endpoints had previously been reported in this lower-BMI subgroup. The November 8 announcement adds noninvasive liver markers to those earlier observations.
However, the announcement does not provide the precise subgroup biopsy response percentages needed to independently compare those outcomes with the full trial.
That limits how much can be concluded from the available summary.
What the Wegovy Liver Marker Results Actually Showed
The November 8 analysis examined liver enzymes, noninvasive fibrosis markers and disease-activity measures at week 72.
Several results favored semaglutide compared with placebo.
For alanine aminotransferase, or ALT, Novo Nordisk reported an estimated treatment ratio of 0.61, with a 95% confidence interval of 0.48 to 0.79.
ALT is an enzyme commonly measured in blood tests. Elevated levels can indicate liver injury, although ALT alone cannot establish the presence or severity of fibrosis.
For aspartate aminotransferase, or AST, the estimated treatment ratio was 0.67, with a 95% confidence interval of 0.56 to 0.80.
These ratios indicate lower estimated enzyme measurements with semaglutide relative to placebo at the assessed time point. They should not be interpreted as percentages of participants whose liver disease resolved.
The Enhanced Liver Fibrosis score, or ELF, also favored semaglutide. Novo reported an estimated treatment difference of -0.45 points, with a 95% confidence interval from -0.73 to -0.17.
ELF combines blood biomarkers associated with liver fibrosis. It provides information about fibrotic disease activity but does not directly replace a liver biopsy or demonstrate that clinical complications have been prevented.
Another fibrosis-related biomarker, PRO-C3, showed an estimated treatment ratio of 0.82, with a 95% confidence interval of 0.71 to 0.95.
PRO-C3 reflects processes related to type III collagen formation, making it useful in research investigating liver fibrogenesis.
The FibroScan-AST, or FAST, score favored semaglutide with an estimated treatment difference of -0.13 points, with a 95% confidence interval from -0.26 to -0.01.
Liver stiffness measured by vibration-controlled transient elastography also moved in a favorable direction, with an estimated treatment ratio of 0.88.
But the 95% confidence interval, 0.73 to 1.06, included 1.0. That means this individual comparison did not establish a statistically significant difference between semaglutide and placebo.
These figures come from Novo Nordisk’s November 8 announcement. HCPLive reported slightly different numerical estimates for several measures, including AST, FAST, ELF and liver stiffness. The underlying presentation or complete analysis would be needed to reconcile the discrepancy definitively.
Viewed together, the manufacturer’s reported estimates suggest a consistent favorable pattern across several markers of liver injury, disease activity and fibrosis.
They do not demonstrate that the drug prevented cirrhosis, liver failure or liver-related death in these 106 participants.
Several liver markers improved. That is encouraging evidence of biological activity, not proof of long-term protection against liver failure.
Does Semaglutide Help the Liver Beyond Weight Loss?
The larger question is whether semaglutide’s liver benefits are entirely explained by weight reduction.
Weight loss can improve metabolic dysfunction, reduce liver fat and improve conditions associated with MASH. The full ESSENCE trial showed substantial weight reduction with semaglutide, making weight loss an important potential contributor to its liver effects.
But body weight is only one component of metabolic health.
People without obesity can still experience insulin resistance, abnormal fat distribution, metabolic inflammation and liver injury.
That is why the lower-BMI subgroup matters.
If semaglutide improves liver-related measures in patients with less excess body weight, the findings challenge the assumption that treatment benefit should be considered only through the lens of obesity.
They do not, however, prove a weight-independent mechanism.
Participants with BMI below 27 can still lose body weight. Without an analysis that adequately separates weight change from treatment effects, researchers cannot establish how much of the observed improvement is attributable to weight reduction and how much might involve other biological pathways.
The available November summary does not provide a sufficiently detailed breakdown of weight changes within this subgroup to resolve that question.
That distinction has practical implications.
A patient with obesity and advanced MASH may benefit from weight reduction alongside improvements in liver disease. A patient with similar liver fibrosis but substantially lower body weight presents a different balance of potential benefits, adverse effects and treatment goals.
Semaglutide remains a weight-reducing medication, regardless of the reason it is prescribed. Appetite suppression, gastrointestinal adverse effects and the possibility of unwanted additional weight loss remain relevant considerations.
Schattenberg told HCPLive that the findings appeared favorable across BMI categories and reported no difference in safety signals between the lower- and higher-BMI groups.
That statement is reassuring, but the summarized data do not provide a detailed lower-BMI safety table or precise rates of adverse events and treatment discontinuation.
In the broader treatment landscape, weight-neutral and weight-reducing approaches to MASH may serve different patients. Grey Pepper recently examined real-world comparisons involving Wegovy and Rezdiffra, which also raise questions about how clinicians select treatments for patients with different metabolic profiles.
Those observational comparisons should not be treated as substitutes for randomized head-to-head clinical trials.
The chemistry of semaglutide adds another layer. It is a modified peptide designed to remain active for approximately a week, in part through interactions with albumin, as Grey Pepper explored in its examination of semaglutide’s half-life engineering.
That engineering makes sustained GLP-1 receptor stimulation possible. It does not, by itself, establish a direct antifibrotic effect independent of weight loss.
Liver disease does not require obesity. But proving that a treatment works independently of weight loss requires more than studying patients who start at a lower BMI.
Why the 106-Person Analysis Is Promising but Not Definitive
The evidence comes with several limitations.
First, the analysis was post hoc. The main ESSENCE trial was randomized and controlled, but this particular subgroup investigation was exploratory rather than a separately powered primary analysis.
Second, 106 participants is a relatively small population. Small subgroups can contain imbalances that affect apparent treatment differences and make estimates less precise.
Third, the subgroup was predominantly Asian and female, with more than half of participants having type 2 diabetes.
That demographic composition is scientifically useful because MASH affects diverse populations. It also makes it inappropriate to assume identical effects in every lower-BMI patient population.
Fourth, the newly presented outcomes were mainly blood-based and imaging-derived markers.
They provide useful evidence about liver injury, fibrotic activity and disease-related measurements. They do not directly tell researchers whether fewer patients developed cirrhosis, required liver transplantation or died from liver disease.
Fifth, the available announcement does not provide complete information about weight loss, adverse events, treatment adherence or discontinuation specifically among the 106 participants.
Those details are particularly important when assessing a weight-reducing drug in people who do not have obesity.
The analysis was also announced by Novo Nordisk, the manufacturer of Wegovy. That does not invalidate the results, but it makes independent review of the detailed presentation and eventual peer-reviewed reporting important.
Finally, the full ESSENCE trial has not completed its clinical-outcomes phase.
The 240-week follow-up is intended to determine whether the earlier improvements in liver histology translate into fewer serious liver-related events.
The FDA has required confirmatory clinical evidence under Wegovy’s accelerated approval pathway. The required trial is scheduled for completion in 2029, although final reporting and regulatory decisions may follow a different timeline.
A dedicated trial in lower-BMI MASH patients would offer an even cleaner answer, particularly if it reported biopsy outcomes, weight changes, tolerability and long-term clinical events within a population specifically selected for that question.
Until then, the November analysis is best read as supporting evidence that semaglutide’s liver-related benefits may extend to patients without obesity.
It does not prove that all such patients will benefit, that weight loss is irrelevant or that long-term complications will be prevented.
The larger significance is the reframing.
MASH has often been discussed as a consequence of excess body weight, but the disease is not limited to patients with obesity. Fibrosis and metabolic dysfunction can occur across different body sizes, and treatment decisions cannot be reduced to BMI alone.
For Wegovy, the new ESSENCE analysis strengthens the argument that lower-BMI patients deserve attention in clinical research and treatment discussions.
It does not settle which treatments are best for them.
The important finding is not that weight no longer matters. It is that body weight alone may be a poor guide to who has serious liver disease and who might benefit from treating it.
Sources and Further Reading
- Novo Nordisk. Post Hoc Analysis of Wegovy 2.4 mg in Adults With MASH and BMI Below 27 kg/m², presented at AASLD The Liver Meeting 2026. November 8, 2026.
- HCPLive. ESSENCE: Semaglutide Improves Liver Markers in MASH Without Obesity. November 8, 2026.
- Sanyal AJ, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. New England Journal of Medicine, 2025. DOI: 10.1056/NEJMoa2413258.
- US Food and Drug Administration. FDA Approves Treatment for Serious Liver Disease Known as MASH. August 2025.
- US Food and Drug Administration. Ongoing Accelerated Approvals: Wegovy MASH Indication and Confirmatory Trial Requirements.
- Grey Pepper. Wegovy and Rezdiffra: Real-World MASH Data Presented at AASLD 2026.
- Grey Pepper. How Semaglutide’s Half-Life Was Extended Through Peptide Engineering.
